001     265958
005     20240403103732.0
024 7 _ |a pmc:PMC10647047
|2 pmc
024 7 _ |a 10.1186/s12888-023-05346-y
|2 doi
024 7 _ |a pmid:37964300
|2 pmid
024 7 _ |a altmetric:156452845
|2 altmetric
037 _ _ |a DZNE-2023-01081
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Lütt, A.
|b 0
245 _ _ |a An explorative single-arm clinical study to assess craving in patients with alcohol use disorder using Virtual Reality exposure (CRAVE)-study protocol.
260 _ _ |a Heidelberg
|c 2023
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1700491428_2200
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Alcohol use disorder (AUD) belongs to the most burdensome clinical disorders worldwide. Current treatment approaches yield unsatisfactory long-term effects with relapse rates up to 85%. Craving for alcohol is a major predictor for relapse and can be intentionally induced via cue exposure in real life as well as in Virtual Reality (VR). The induction and habituation of craving via conditioned cues as well as extinction learning is used in Cue Exposure Therapy (CET), a long-known but rarely used strategy in Cognitive Behavioral Therapy (CBT) of AUD. VR scenarios with alcohol related cues offer several advantages over real life scenarios and are within the focus of current efforts to develop new treatment options. As a first step, we aim to analyze if the VR scenarios elicit a transient change in craving levels and if this is measurable via subjective and psychophysiological parameters.A single-arm clinical study will be conducted including n = 60 patients with AUD. Data on severity of AUD and craving, comorbidities, demographics, side effects and the feeling of presence in VR will be assessed. Patients will use a head-mounted display (HMD) to immerse themselves into three different scenarios (neutral vs. two target situations: a living room and a bar) while heart rate, heart rate variability, pupillometry and electrodermal activity will be measured continuously. Subjective craving levels will be assessed before, during and after the VR session.Results of this study will yield insight into the induction of alcohol craving in VR cue exposure paradigms and its measurement via subjective and psychophysiological parameters. This might be an important step in the development of innovative therapeutic approaches in the treatment of patients with AUD.This study was approved by the Charité-Universitätsmedizin Berlin Institutional Review Board (EA1/190/22, 23.05.2023). It was registered on ClinicalTrials.gov (NCT05861843).
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Alcohol Use Disorder
|2 Other
650 _ 7 |a Craving
|2 Other
650 _ 7 |a Cue Exposure Therapy
|2 Other
650 _ 7 |a Electrodermal activity
|2 Other
650 _ 7 |a Heart rate variability
|2 Other
650 _ 7 |a Psychophysiological parameters
|2 Other
650 _ 7 |a Pupillometry
|2 Other
650 _ 7 |a Virtual Reality
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Alcohol Drinking
|2 MeSH
650 _ 2 |a Alcoholism: therapy
|2 MeSH
650 _ 2 |a Alcoholism: psychology
|2 MeSH
650 _ 2 |a Craving
|2 MeSH
650 _ 2 |a Cues
|2 MeSH
650 _ 2 |a Recurrence
|2 MeSH
650 _ 2 |a Virtual Reality
|2 MeSH
700 1 _ |a Tsamitros, N.
|b 1
700 1 _ |a Wolbers, T.
|0 P:(DE-2719)2810583
|b 2
|u dzne
700 1 _ |a Rosenthal, A.
|b 3
700 1 _ |a Bröcker, A. L.
|b 4
700 1 _ |a Schöneck, R.
|b 5
700 1 _ |a Bermpohl, F.
|b 6
700 1 _ |a Heinz, A.
|b 7
700 1 _ |a Beck, A.
|b 8
700 1 _ |a Gutwinski, S.
|b 9
773 _ _ |a 10.1186/s12888-023-05346-y
|g Vol. 23, no. 1, p. 839
|0 PERI:(DE-600)2050438-X
|n 1
|p 839
|t BMC psychiatry
|v 23
|y 2023
|x 1471-244X
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/265958/files/DZNE-2023-01081.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/265958/files/DZNE-2023-01081.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:265958
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2810583
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2023
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BMC PSYCHIATRY : 2022
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2023-05-02T09:05:40Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2023-05-02T09:05:40Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Open peer review
|d 2023-05-02T09:05:40Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-08-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-28
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2023-08-28
920 1 _ |0 I:(DE-2719)1310002
|k AG Wolbers
|l Aging, Cognition and Technology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1310002
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21